Acorda Named One of the 100 Best Workplaces for Women by Fortune and Great Place to Work
September 30 2015 - 6:15AM
Business Wire
Acorda Therapeutics, Inc. (Nasdaq:ACOR) has been named as one of
the 100 Best Workplaces for Women based on an independent survey by
Fortune and Great Place to Work®. The survey included more than
135,600 female employees at companies of all sizes based in the
United States. This recognition is based on women’s assessments of
the quality and fairness of their workplace.
“Acorda is focused on developing medicines that can change
people’s lives. To do so successfully requires close collaboration
among people with a wide diversity of perspectives and experiences,
and rewards based solely on performance. Our culture emphasizes
these values, while also fostering work/home life balance,” said
Denise Duca, Executive Vice President, Human Resources of Acorda.
“We are proud that the talented women who work at Acorda view this
as a great place to build a career and to make valuable
contributions to advancing healthcare.”
In addition to being named as one of the Best Workplaces for
Women in 2015, Acorda has been recognized as one of the Best Places
to Work in New York for the past five years in a row by the Best
Companies Group, ranking 3rd in 2015 among large employers (250+
associates).
Factors such as the fairness of promotions, access to
information and leadership, level of support for employees’
personal lives, and degree of inclusiveness and connection with
colleagues were inclusion criteria for the Best Workplaces for
Women list. Scores also take into account how well-represented
women are within the workforce, management and executive positions;
how positively women experience their workplace’s fairness; and how
favorable women’s experiences are compared to the 138,000 men also
surveyed.
The analysis showed that the companies recognized as Best
Workplaces for Women create a more consistent and inclusive
environment across a range of day-to-day trust-building behaviors,
including employees’ access to special recognition, fair treatment
regardless of role, and management approachability.
About Acorda Therapeutics
Founded in 1995, Acorda Therapeutics is a
biotechnology company focused on developing therapies that restore
function and improve the lives of people with neurological
disorders.
Acorda markets three FDA-approved therapies, including
AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg. The
Company has one of the leading pipelines in the industry of novel
neurological therapies. Acorda is currently developing a number of
clinical and preclinical stage therapies. This pipeline addresses a
range of disorders including post-stroke walking deficits,
Parkinson’s disease, epilepsy, heart failure, MS and spinal cord
injury.
For more information, please visit the Company’s website
at: www.acorda.com.
Forward Looking Statements
This press release includes forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. All statements, other than statements of historical facts,
regarding management's expectations, beliefs, goals, plans or
prospects should be considered forward-looking. These statements
are subject to risks and uncertainties that could cause actual
results to differ materially, including the ability to realize the
benefits anticipated from the Civitas transaction and to
successfully integrate Civitas' operations into our operations; our
ability to successfully market and sell Ampyra in the U.S.; third
party payers (including governmental agencies) may not reimburse
for the use of Ampyra or our other products at acceptable rates or
at all and may impose restrictive prior authorization requirements
that limit or block prescriptions; the risk of unfavorable results
from future studies of Ampyra or from our other research and
development programs, including CVT-301, Plumiaz (diazepam) Nasal
Spray, or any other acquired or in-licensed programs; we may not be
able to complete development of, obtain regulatory approval for, or
successfully market CVT-301, Plumiaz, or any other products under
development; we may need to raise additional funds to finance our
expanded operations and may not be able to do so on acceptable
terms; the occurrence of adverse safety events with our products;
delays in obtaining or failure to obtain regulatory approval of or
to successfully market Fampyra outside of the U.S. and our
dependence on our collaboration partner Biogen in connection
therewith; competition; failure to protect our intellectual
property, to defend against the intellectual property claims of
others or to obtain third party intellectual property licenses
needed for the commercialization of our products; and, failure to
comply with regulatory requirements could result in adverse action
by regulatory agencies.
These and other risks are described in greater detail
in Acorda Therapeutics' filings with the Securities
and Exchange Commission. Acorda may not actually achieve the goals
or plans described in its forward-looking statements, and investors
should not place undue reliance on these statements.
Forward-looking statements made in this release are made only as of
the date hereof, and Acorda disclaims any intent or obligation to
update any forward-looking statements as a result of developments
occurring after the date of this release.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20150930005078/en/
Acorda TherapeuticsJeff Macdonald,
914-326-5232jmacdonald@acorda.com
Acorda Therapeutics (NASDAQ:ACOR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Acorda Therapeutics (NASDAQ:ACOR)
Historical Stock Chart
From Apr 2023 to Apr 2024